Sokolowska Izabela, Ngounou Wetie Armand G, Wormwood Kelly, Thome Johannes, Darie Costel C, Woods Alisa G
Biochemistry and Proteomics Group, Department of Chemistry and Biomolecular Science, Clarkson University, 8 Clarkson Avenue, Potsdam, NY, 13699-5810, USA.
J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S9-18. doi: 10.1007/s00702-013-1134-6. Epub 2013 Dec 20.
The etiology and pathogenesis of many psychiatric disorders are unclear with many signaling pathways and complex interactions still unknown. Primary information provided from gene expression or brain activity imaging experiments is useful, but can have limitations. There is a current effort focusing on the discovery of diagnostic and prognostic proteomic potential biomarkers for psychiatric disorders. Despite this work, there is still no biological diagnostic test available for any mental disorder. Biomarkers may advance the care of psychiatric illnesses and have great potential to knowledge of psychiatric disorders but several drawbacks must be considered. Here, we describe the potential of proteomic biomarkers for better understanding and diagnosis of psychiatric disorders and current putative biomarkers for schizophrenia, depression, autism spectrum disorder and attention deficit/hyperactivity disorder.
许多精神疾病的病因和发病机制尚不清楚,许多信号通路和复杂的相互作用仍不为人知。基因表达或脑活动成像实验提供的原始信息很有用,但可能存在局限性。目前正在努力发现用于精神疾病的诊断和预后蛋白质组学潜在生物标志物。尽管有这项工作,但仍没有针对任何精神障碍的生物学诊断测试。生物标志物可能会改善精神疾病的治疗,并在精神疾病知识方面具有巨大潜力,但必须考虑几个缺点。在这里,我们描述了蛋白质组学生物标志物在更好地理解和诊断精神疾病方面的潜力,以及目前用于精神分裂症、抑郁症、自闭症谱系障碍和注意力缺陷多动障碍的假定生物标志物。